Alexander Rumyantsev

• GPH of the middle/late clinical stage COVID-19 vaccine program coordinating cross-functional team: R&D strategy and clinical plans for primary and booster COVID-19 prevention indications. • Secured over $9M of funding from CEPI. Chair in the JSC collaborative program • Led Phase 3 platform clinical study evaluating heterologous booster with a subunit COVID-19 vaccine (NCT05293665). The clinical trial met its primary and secondary endpoints. The first study to demonstrate non-inferiority and superiority of immune responses after a heterologous booster in a head-to-head comparison to COVID-19 vaccine platforms (mRNA, adenovirus vectored, and inactivated virus). • Supported regulatory and market authorizations; successful submission with MHRA (UK)/TGA (Australia). MAA decision is imminent. • Medical Lead, Phase 1 dose-escalation study of a PSCK9 vaccine candidate. The study is ongoing • Supervised safety monitoring across all clinical programs at Vaxxinity

Developed strategic plans and insights to expand R&D portfolio. Managed licensing negotiations. • Senior member of external R&D team in North America, acted as a Head: managed a team of MD and PhD experts • Personally identified critical innovations by evaluating 650+ opportunities and pursuing projects with optimal ROI. • Guided cross-functional evaluation teams to establish 75 partnerships on vaccines, antibodies, adjuvants, protein expression, mRNA and other vectors, diagnostics, and other vaccine related technologies. • Two partnered RSV programs (live-virus vaccine and monoclonal antibody) are in late clinical development pipeline. • Served as a strategic and scientific leader in viral vaccines. Built corporate strategic positions for seven programs comprising drug delivery, diagnostics, and emerging infections. Helped securing five collaborative agreements with U.S. Government and academic organizations.

Governed virology department operations and research strategy. Established novel viral vectored platform for vaccine candidates against human and veterinary targets. • Developed and directed research activities of a preclinical Virology team, including antigen design, characterization, immune assays, and animal studies. Mentored research graduation projects of biotech interns. • GPH of a preclinical Tick-Borne Encephalitis program: created preclinical research plan for TBE prevention indication and viral vector strategy for multiple human and veterinary targets. • Managed cross-functional program team; liaised with international stakeholders to define technical and market risks to guarantee program success; administered the project and collaborative research budgets. • Authored scientific publications, patents and patent applications. Presented research findings at multiple national and international scientific conferences.

Postdoctoral fellow. Led development of live attenuated vaccines against emerging flaviviruses. • Developed several attenuating strategies and managed international collaborations • Two vaccine candidates (West Nile Virus and TBE) tested in clinical studies, WNV out licensed to MacroGenics in 2005. • Achievements recognized by Fellows Award for Research Excellence (2005) and NIH MERIT award (2005)